Literature DB >> 9358023

VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries.

M Laitinen1, I Zachary, G Breier, T Pakkanen, T Häkkinen, J Luoma, H Abedi, W Risau, M Soma, M Laakso, J F Martin, S Ylä-Herttuala.   

Abstract

Thickening of the arterial intima and smooth muscle cell (SMC) proliferation remain major problems after vascular surgery and other types of vascular manipulations. We studied the effect of endothelial cell (EC)-specific vascular endothelial growth factor (VEGF) gene transfer on the thickening of the intima using a silicone collar inserted around carotid arteries that acted both as the agent that caused intimal SMC growth and as a reservoir for the transfected gene. The model preserved EC integrity and permitted direct extravascular gene transfer without any intravascular manipulation. Compared to beta-galactosidase (lacZ)-transfected control arteries, plasmid/liposome-mediated VEGF gene transfer significantly reduced intimal thickening 1 week after the gene transfer. Administration to the experimental animals of the nitric oxide (NO) synthase inhibitor L-NAME abolished the difference in intimal thickening between VEGF and lacZ-transfected arteries. Furthermore, VEGF caused NO release from cultured human umbilical vein EC. It is concluded that extravascular VEGF gene transfer attenuates intimal growth and could be useful for the prevention of intimal thickening during vascular surgery. Our results further suggest that VEGF may reduce SMC proliferation via a mechanism that involves VEGF-induced NO production from the endothelium.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9358023     DOI: 10.1089/hum.1997.8.15-1737

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  22 in total

Review 1.  Clinical applications of vascular gene therapy.

Authors:  J Rutanen; T T Rissanen; A Kivelä; I Vajanto; S Ylä-Herttuala
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

2.  Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology.

Authors:  Em Dietrich; K Antoniades
Journal:  Hippokratia       Date:  2012-07       Impact factor: 0.471

Review 3.  Gene transfer to the vasculature: historical perspective and implication for future research objectives.

Authors:  Sarah J George; Andrew H Baker
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

4.  Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells.

Authors:  R Abu-Ghazaleh; J Kabir; H Jia; M Lobo; I Zachary
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

Review 5.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

6.  Proliferation of endothelial cell on polytetrafluoroethylene vascular graft materials carried VEGF gene plasmid.

Authors:  Si-feng Tao; Li Chen; Yi-xiong Zheng; Yuan Xu; Jian Chen; Hong Yu
Journal:  J Zhejiang Univ Sci B       Date:  2006-06       Impact factor: 3.066

7.  Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A.

Authors:  Miho Nozaki; Eiji Sakurai; Brian J Raisler; Judit Z Baffi; Jassir Witta; Yuichiro Ogura; Rolf A Brekken; E Helene Sage; Balamurali K Ambati; Jayakrishna Ambati
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

Review 8.  Gene therapy for restenosis: current status.

Authors:  Juha Rutanen; Johanna Markkanen; Seppo Ylä-Herttuala
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C.

Authors:  Maria G Stathopoulou; Amélie Bonnefond; Ndeye Coumba Ndiaye; Mohsen Azimi-Nezhad; Said El Shamieh; Abdelsalam Saleh; Marc Rancier; Gerard Siest; John Lamont; Peter Fitzgerald; Sophie Visvikis-Siest
Journal:  J Lipid Res       Date:  2012-12-02       Impact factor: 5.922

10.  Cardiotoxicity associated with targeted cancer therapies.

Authors:  Z I Chen; D I Ai
Journal:  Mol Clin Oncol       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.